Q/C TECHNOLOGIES, INC. (QCLS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US62856X3008
Q/C TECHNOLOGIES, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -9.85 m USD |
| EBIT | -11.85 m USD |
| Net income | -11.63 m USD |
| Diluted EPS – continuing operations | -8.66 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Q/C TECHNOLOGIES, INC.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
More stocks
- VACCINEX, INC. (VCNX)
- Toppoint Holdings Inc. (TOPP)
- PRINCETON CAPITAL CORP (PIAC)
- BIOXYTRAN, INC (BIXT)
- CEA Industries Inc. (BNC)
- AIBOTICS, INC. (AIBT)
- King Resources, Inc. (KRFG)
- Trillion Energy International Inc. (TRLEF)
- reAlpha Tech Corp. (AIRE)
- Yellowstone Group Ltd. (YSGL)
- Bluejay Diagnostics, Inc. (BJDX)
- Power REIT (PW)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.